355 related articles for article (PubMed ID: 35878625)
41. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
[TBL] [Abstract][Full Text] [Related]
42. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
43. Self-collected vaginal sampling for the detection of genital human papillomavirus (HPV) using careHPV among Ghanaian women.
Obiri-Yeboah D; Adu-Sarkodie Y; Djigma F; Hayfron-Benjamin A; Abdul L; Simpore J; Mayaud P
BMC Womens Health; 2017 Sep; 17(1):86. PubMed ID: 28950841
[TBL] [Abstract][Full Text] [Related]
44. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
45. Cervical Visual Inspection with Acetic Acid (VIA) and Oncogenic Human Papillomavirus Screening in Rural Indigenous Guatemalan Women: Time to Rethink VIA.
Jeffries A; Beck-Sagué CM; Marroquin-Garcia AB; Dean M; McCoy V; Cordova-Toma DA; Fenkl E; Madhivanan P
Int J Environ Res Public Health; 2021 Nov; 18(23):. PubMed ID: 34886133
[TBL] [Abstract][Full Text] [Related]
46. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.
Schiffman M; Herrero R; Hildesheim A; Sherman ME; Bratti M; Wacholder S; Alfaro M; Hutchinson M; Morales J; Greenberg MD; Lorincz AT
JAMA; 2000 Jan; 283(1):87-93. PubMed ID: 10632285
[TBL] [Abstract][Full Text] [Related]
47. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
48. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
49. Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial.
Pretsch PK; Spees LP; Brewer NT; Hudgens MG; Sanusi B; Rohner E; Miller E; Jackson SL; Barclay L; Carter A; Wheeler SB; Smith JS
Lancet Public Health; 2023 Jun; 8(6):e411-e421. PubMed ID: 37182529
[TBL] [Abstract][Full Text] [Related]
50. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
[TBL] [Abstract][Full Text] [Related]
51. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
52. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
[TBL] [Abstract][Full Text] [Related]
53. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
[TBL] [Abstract][Full Text] [Related]
54. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
[TBL] [Abstract][Full Text] [Related]
55. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
56. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
57. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
58. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients.
Reisner SL; Deutsch MB; Peitzmeier SM; White Hughto JM; Cavanaugh TP; Pardee DJ; McLean SA; Panther LA; Gelman M; Mimiaga MJ; Potter JE
PLoS One; 2018; 13(3):e0190172. PubMed ID: 29538411
[TBL] [Abstract][Full Text] [Related]
59. Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol.
Almonte M; Murillo R; Sánchez GI; González P; Ferrera A; Picconi MA; Wiesner C; Cruz-Valdez A; Lazcano-Ponce E; Jerónimo J; Ferreccio C; Kasamatsu E; Mendoza L; Rodríguez G; Calderón A; Venegas G; Villagra V; Tatti S; Fleider L; Terán C; Baena A; Hernández ML; Rol ML; Lucas E; Barbier S; Ramírez AT; Arrossi S; Rodríguez MI; González E; Celis M; Martínez S; Salgado Y; Ortega M; Beracochea AV; Pérez N; Rodríguez de la Peña M; Ramón M; Hernández-Nevarez P; Arboleda-Naranjo M; Cabrera Y; Salgado B; García L; Retana MA; Colucci MC; Arias-Stella J; Bellido-Fuentes Y; Bobadilla ML; Olmedo G; Brito-García I; Méndez-Herrera A; Cardinal L; Flores B; Peñaranda J; Martínez-Better J; Soilán A; Figueroa J; Caserta B; Sosa C; Moreno A; Mural J; Doimi F; Giménez D; Rodríguez H; Lora O; Luciani S; Broutet N; Darragh T; Herrero R
BMJ Open; 2020 May; 10(5):e035796. PubMed ID: 32448795
[TBL] [Abstract][Full Text] [Related]
60. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
